Rocket Pharmaceuticals, Inc.
RCKT Nasdaq
SEC CIK 1281895
Follow Rocket Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$49.2M
+2.2% vs same quarter last year
EPS, diluted
−$0.43
+4.4% vs same quarter last year
Operating cash flow
−$39.1M
+22.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$223.1M |
| FY24 | $0 | −$258.7M |
| FY23 | $0 | −$245.6M |
| FY22 | $0 | −$221.9M |
| FY21 | $0 | −$169.1M |
| FY20 | $0 | −$139.7M |
| FY19 | $0 | −$77.3M |
| FY18 | $0 | −$74.5M |
| FY17 | $0 | −$19.6M |
| FY16 | $0 | −$7.6M |
| FY15 | - | −$68M |
| FY14 | - | −$9.5M |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$190.5M |
| FY24 | −$215.6M |
| FY23 | −$211.4M |
| FY22 | −$186.5M |
| FY21 | −$128.8M |
| FY20 | −$95.2M |
| FY19 | −$87.9M |
| FY18 | −$55.2M |
| FY17 | −$16.7M |
| FY16 | −$5.8M |
| FY15 | −$17.8M |
| FY14 | - |
| FY13 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | $0 |
| FY20 | $72K |
| FY19 | $0 |
| FY18 | $0 |
| FY17 | $0 |
| FY16 | $0 |
| FY15 | - |
| FY14 | - |
| FY13 | - |